pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Antibiotics use between therapeutic drug monitoring (TDM) and non-TDM groups
| TDM (n = 27) | non-TDM (n = 27) | Total (n = 54) | ||
|---|---|---|---|---|
| Penicillins, N(%) | 4 (14.8) | 3 (11.1) | 7 (13.0) | 1.000 |
| Pip/Tazo, N(%) | 14 (51.9) | 10 (37.0) | 24 (44.4) | 0.273 |
| Cephalosporins, N(%) | ||||
| 2ndgeneration | 1 (3.7) | 2 (7.4) | 3 (5.6) | 1.000 |
| 3rd generation | 19 (70.4) | 14 (51.9) | 33 (61.1) | 0.163 |
| 4th generation | 11 (40.7) | 8 (29.6) | 19 (35.2) | 0.393 |
| Carbapenems, N(%) | 21 (77.8) | 19 (70.4) | 40 (74.1) | 0.535 |
| Fluoroquinolones, N(%) | 25 (92.6) | 20 (74.1) | 45 (83.3) | 0.142 |
| Aminoglycosides, N(%) | 17 (63.0) | 11 (40.7) | 28 (51.9) | 0.102 |
| Macrolides, N(%) | 9 (33.3) | 7 (25.9) | 16 (29.6) | 0.551 |
| Tetracyclines, N(%) | 2 (7.4) | 1 (3.7) | 3 (5.6) | 1.000 |
| Glycopeptides, N(%) | 21 (77.8) | 18 (66.7) | 39 (72.2) | 0.362 |
| Oxazolidinones, N(%) | 5 (18.5) | 2 (7.4) | 7 (13.0) | 0.420 |
| Polymyxins, N(%) | 14 (51.9) | 8 (29.6) | 22 (40.7) | 0.097 |
| Metronidazole, N(%) | 10 (37.0) | 6 (22.2) | 16 (29.6) | 0.233 |
| TMP/SMX, N(%) | 26 (96.3) | 23 (85.2) | 49 (90.7) | 0.159 |
Data are the No. (%)
From the Chi-square test or Fisher’s exact test
Pip/Tazo, piperacillin/tazobactam; TMP/SMX, trimethoprim/sulfamethoxazole